PCNS-DLBCL is a rare extranodal non-Hodgkin lymphoma that primarily affects the brain, spine, or vitreoretinal space. The prognosis for PCNS-DLBCL is significantly worse than that for its systemic counterpart.
Understanding how and where this tumor initiates, and how it survives or depends on the microenvironment of the CNS is key to understanding the underlying biology and identifying reliable biomarkers for selecting personalized therapy or for biologically directed therapy that could improve the cure rate of CNS lymphomas.
Be an adult immunocompetent patient who received a PCNS-DLBCL diagnosis according to the WHO-HAEM5 criteria between 2018 and 2024.
Availability of formalin-fixed paraffin-embedded (FFPE) diagnostic tumor material.
Availability of the baseline and follow-up annotations
Established immunodeficiency conditions.
Secondary CNS localizations of DLBCL
Transformed DLBCL
Adults patients with primary central nervous system diffuse large B cell lymphoma (PCNS-DLBCL)
Cohort
Retrospective
Not listed
Prevalence of non-GC phenotype
Prevalence of mutations, copy number abnormalities, and structural variants
Prevalence of PCNS-DLBCL molecular subtypes defined by genetic lesions
Prevalence of PCNS-DLBCL molecular subtypes defined by gene expression signatures
Prevalence of molecular features of clinical, laboratory, and radiological features
Prevalence of PCNS-DLBCL immunological signatures defined by gene expression profiling
3. Prevalence of PCNS-DLBCL MicroRNA signatures defined by miRNOMA evaluation
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
